Background Paxlovid was granted an Emergency Use Authorization for the treatment of mild
to moderate coronavirus disease 2019 (COVID-19), based on the interim analysis of the …

Among US adults diagnosed with COVID-19, including those with previous infection or
vaccination, persons who were prescribed Paxlovid within 5 days of diagnosis had a 51 …

Summary Background Nirmatrelvir plus ritonavir (Paxlovid) reduced the risk of
hospitalization or death by 89% in high-risk, ambulatory adults with COVID-19. We aimed at …

Introduction Elderly patients are the most affected and vulnerable to COVID-19 and effective
therapeutic interventions are urgently required. We clarified the safety and efficacy of …

We read with interest the manuscript “Sensitivity and specificity of surveillance case
definitions in detection of influenza and respiratory syncytial virus among hospitalized …

The COVID-19 pandemic is one of the greatest threats to human health in the 21st century
with more than 257 million cases and over 5.17 million deaths reported worldwide (as of …

In comments to Bloomberg published on May 3, 2022, Pfizer chief executive officer Albert
Bourla suggested that patients who experience a relapse of symptoms after finishing a …

Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment
— California, December 2021–May 2022 | MMWR Skip directly to site content Skip directly to …

Pfizer's oral antiviral drug paxlovid significantly reduces hospital admissions and deaths
among people with covid-19 who are at high risk of severe illness, when compared with …

The quest for effective drugs to treat COVID-19 has been a priority since the outbreak of the
disease. The clinical application of remdesivir has been greatly restricted by the need for …